Evidence map›Paper›PMID 38559131›Full record

ArticleResearch square2024

Neuronal alterations in AKT isotype expression in schizophrenia.

Emily A Devine, Ali S Imami, Hunter Eby, Abdul-Rizaq Hamoud, Hasti Golchin, William Ryan, Smita Sahay, Elizabeth A Shedroff, Taylen Arvay, Alex W Joyce and 4 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Emily A DevineDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Ali S ImamiDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0003-3684-3539
Hunter EbyDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0002-9029-9768
Abdul-Rizaq HamoudDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Hasti GolchinDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0002-2992-9070
William RyanDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Smita SahayDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0009-0003-4377-8963
Elizabeth A ShedroffDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Taylen ArvayDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Alex W JoyceDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Sophie M AsahDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
Consuelo Walss-BassDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA.
Sinead O'DonovanDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0003-3172-4952
Robert E McCullumsmithDepartment of Neuroscience, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.ORCID 0000-0001-6921-7150
University of Toledo · USNeurosciences Institute · USThe University of Texas Health Science Center at Houston · US

Funding

Translational assessment of brain bioenergetic function in schizophreniaR01MH121102 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI MARANO, CHRISTOPHER, MCCULLUMSMITH, ROBERT E · 2020 to 2024
$3.7M
Development of Attenuated Furoxans as Novel Therapies for Alzheimer's DiseaseR01AG057598 · NIA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI SCHIEFER, ISAAC T · 2018 to 2022
$2.3M
Cell-specific analysis of sub-kinomes in schizophreniaR01MH107487 · NIMH · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI MCCULLUMSMITH, ROBERT E, MELLER, JAREK · 2016 to 2020
$1.9M
Training in Molecular and translational Cell DynamicsT32GM144873 · NIGMS · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI AVIDOR-REISS, TOMER, DWORKIN, LANCE DOUGLAS · 2022 to 2024
$1.3M
NIA NIH HHS R01 AG057598NIGMS NIH HHS T32 GM144873NIMH NIH HHS R01 MH107487NIMH NIH HHS R01 MH121102
6 · The paper itself

Abstract

Schizophrenia is characterized by substantial alterations in brain function, and previous studies suggest insulin signaling pathways, particularly involving AKT, are implicated in the pathophysiology of the disorder. This study demonstrates elevated mRNA expression of AKT1-3 in neurons from schizophrenia subjects, contrary to unchanged or diminished total AKT protein expression reported in previous postmortem studies, suggesting a potential decoupling of transcript and protein levels. Sex-specific differential AKT activity was observed, indicating divergent roles in males and females with schizophrenia. Alongside AKT, upregulation of PDPK1, a critical component of the insulin signaling pathway, and several protein phosphatases known to regulate AKT were detected. Moreover, enhanced expression of the transcription factor FOXO1, a regulator of glucose metabolism, hints at possible compensatory mechanisms related to insulin signaling dysregulation. Findings were largely independent of antipsychotic medication use, suggesting inherent alterations in schizophrenia. These results highlight the significance of AKT and related signaling pathways in schizophrenia, proposing that these changes might represent a compensatory response to a primary defect of conical insulin signaling pathways. This research underscores the need for a detailed understanding of these signaling pathways for the development of effective therapeutic strategies.

Identifiers

PMID38559131
PMCPMC10980160
OpenAlexW4392752708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.